Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Revenue (2023 - 2025)

CG Oncology's Revenue history spans 3 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 409.21% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $4.0 million, up 254.7%, while the annual FY2025 figure was $4.0 million, 254.7% up from the prior year.
  • Revenue reached $2.3 million in Q4 2025 per CGON's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.3 million in Q4 2025 to a low of $1000.0 in Q4 2023.
  • Average Revenue over 3 years is $538300.0, with a median of $152500.0 recorded in 2023.
  • Peak YoY movement for Revenue: surged 45500.0% in 2024, then plummeted 90.17% in 2025.
  • A 3-year view of Revenue shows it stood at $1000.0 in 2023, then soared by 45500.0% to $456000.0 in 2024, then soared by 409.21% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Revenue are $2.3 million (Q4 2025), $1.7 million (Q3 2025), and $52000.0 (Q1 2025).